Misi He

Misi He

Auto-generated profile, based on publicly available information

Misi He

Department of Gynecologic Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2023 in Clinical Medicine Insights: Oncology
Verified
Journal Article
Open access
XLXingtao Long
Xingtao Long
MHMisi He
Misi He
LYLingling Yang
Lingling Yang
DZDongling Zou
Dongling Zou
DWDong Wang
Dong Wang
QZQi Zhou
Qi Zhou
Background: Risk stratification of patients with cervical cancer accompanied by positive lymph nodes (stage IIIC) (the 2018 International Federation of Gynecology and Obstetrics [FIGO] new staging system) yields a clinically heterogeneous group. In this study, we investigated the prognostic performance of the 2018 FIGO staging system for stage IIIC cervical cancer. Methods: The study included patients with stage III cervical cancer based on the 2018 FIGO staging system, who visited Chongqing University Cancer Hospital between January 2011 and December 2014. Kaplan-Meier curves were generated to evaluate overall survival (OS), which was compared using the log-rank test. The Cox proportional hazard regression model was used for multivariable analysis. Results: A total of 418 patients were eligible for analysis. The 5-year OS was 54.1% for stage IIIC1, 43.3% for stage IIIA, 40.6% for stage IIIB, and 23.1% for stage IIIC2 ( P < .001). Multivariable analysis revealed that compared with stages IIIA (hazard ratio [HR] 1.432, 95% confidence interval [CI] 0.867-2.366, P = .161) and IIIB (HR 1.261, 95% CI 0.871-1.827, P = .219), stage IIIC1 cancer was not significantly associated with an increased mortality risk. Stage IIIC2 was independently associated with an increased mortality risk compared with stages IIIA (HR 2.958, 95% CI 1.757-4.983, P < .001) and IIIB (HR 2.606, 95% CI 1.752-3.877, P < .001). We stratified patients with stage IIIC1 based on the T stage. The 5-year OS was significantly longer in patients with stage IIIC1 (T1) than in those with stage IIIA ( P = .004) or IIIB ( P < .001). Analysis of multiple factors revealed that the mortality risk was 2.75-fold higher in patients with stage IIIC1pN>2 than in patients with stage IIIC1pN1-2 (HR 2.753, 95% CI 1.527-4.965, P = .001). Conclusions: Patients with stage IIIC1 cervical cancer showed heterogeneous clinical characteristics that reflected variable prognoses, depending on the T stage and the extent of pelvic lymph node metastases.

1 January 2023 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
MHMisi He
Misi He
MGMingfang Guo
Mingfang Guo
QZQi Zhou
Qi Zhou
YTYing Tang
Ying Tang
LZLin Zhong
Lin Zhong
DZDongling Zou
Dongling Zou
He M, et al. J Gynecol Oncol. 2023 Mar;34:e55. https://doi.org/10.3802/jgo.2023.34.e55

15 February 2025 in Cancer Letters
Verified
Journal Article
Open access
MGMingfang Guo
Mingfang Guo
MHMisi He
Misi He
YDYun Dang
Yun Dang
LLLi Lei
Li Lei
QLQiaoling Li
Qiaoling Li
DZDongling Zou
Dongling Zou
Para-aortic lymph node (PALN) metastasis of patients with locally advanced cervical cancer (LACC) is associated with multiple risk factors. This study aimed to identify risk factors and develop a predictive model for PALN metastasis based on the pathological diagnosis via surgical staging to determine the patient-population suitable for extended-field irradiation (EFRT) and clarify the prognosis of patients with LACC. Five parameters were identified as predictors by logistic regression analysis. The predictive model was displayed as a nomogram and then modified into a simple scoring system. The concordance indices for the prediction nomogram were 0.939 in the training cohort, and 0.954 in the validation cohort, respectively. The scoring system consisted of tumor size, histological type, number of pelvic lymph nodes (PLNs), common iliac lymph node, and shorter diameter of the largest PLN. With a cutoff value of 8 points, the sensitivity and specificity of the predictive model were 91.04 % and 85.37 %, respectively, in the training cohort, and 89.47 % and 84.68 %, respectively, in the validation cohort. Using this system, patients were divided into high- and low-risk groups. Patients in the high-risk group showed a greater likelihood of PALN metastasis and worse PFS and OS than those in the low-risk group. The predictive model displays promise for the pathological diagnosis of PALN via surgical staging, offering good accuracy. It provides a non-invasive, practical tool to guide precise radiation strategy and stratify prognosis of patients with LACC.

1 January 2024 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
HHHao He
Hao He
MHMisi He
Misi He
QZQi Zhou
Qi Zhou
YTYing Tang
Ying Tang
JWJing Wang
Jing Wang
DZDongling Zou
Dongling Zou
He H, et al. J Gynecol Oncol. 2024 Apr;35:e102. https://doi.org/10.3802/jgo.2024.35.e102

24 September 2025 in ESMO Open
Verified
Journal Article
Open access
QRQ. Rao
Q. Rao
HZH. Zhou
H. Zhou
WWW. Weng
W. Weng
YHY. He
Y. He
NLN. Li
N. Li
BZBingzhong Zhang
Bingzhong Zhang
Endometrial cancer (EC) is among the most prevalent gynecological malignancies worldwide. This study explores the use of cell-free DNA (cfDNA) fragmentomics to develop a non-invasive liquid biopsy assay, aiming to improve early detection, subtyping, and prognostication of EC, thereby enhancing therapeutic outcomes and reducing associated mortality. A cohort of 120 patients with diagnosed EC and 120 healthy volunteers was used to develop a novel non-invasive liquid biopsy assay for EC. Five distinct fragmentomic features were analyzed from preoperative plasma samples using low-pass whole-genome sequencing. Ensemble models were created by integrating base models that utilized four different machine learning algorithms for early cancer detection, clinicopathological subtyping, and prediction of recurrence-free survival. An independent test cohort of 62 EC patients and 62 healthy controls was used to assess the final ensemble model's performance. The liquid biopsy assay demonstrated high efficacy in early EC detection, achieving an area under the curve (AUC) of 0.96, with 75.8% sensitivity and 96.8% specificity in the independent test cohort. Consistent sensitivities were observed across EC stages I-IV at 74.4%, 85.7%, 75%, and 75%, respectively. The assay moderately predicted clinicopathological features including stage (AUC = 0.72), histological subtypes (AUC = 0.73), and microsatellite instability status (AUC = 0.77). The model also effectively predicted recurrence-free survival, identifying high-risk patients [hazard ratio (HR) 8.6, P < 0.001]. Additionally, similarity network fusion stratified patients into high- and low-risk clusters, with high-risk individuals exhibiting a notably increased recurrence risk (HR 6.2, P = 0.049). Patients identified as high-risk by both methods exhibited an even greater risk (HR 10.1, P < 0.0001) for recurrence. This DECIPHER-UCEC-2 study (Detecting Early Cancer by Inspecting ctDNA Features) demonstrates that by integrating cfDNA fragmentomics with machine learning, our liquid biopsy assay shows significant promise for EC's early detection, subtyping, and prognosis, potentially paving the way for enhanced patient outcomes.

1 January 2022
Verified
Conference Paper
Open access
PDF file
MHMisi He
Misi He
DZDongling Zou
Dongling Zou
He M, et al. J Gynecol Oncol. 2022 Aug;33(Suppl 1):S13. https://doi.org/10.3802/jgo.2022.33.S13